{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:56:44Z","timestamp":1792195004361,"version":"4.4.0"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.blre.2019.05.005","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T08:35:15Z","timestamp":1558514115000},"page":"100581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Use of novel therapies in the treatment of light chain amyloidosis"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-5581","authenticated-orcid":false,"given":"Cindy","family":"Varga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Titus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Toskic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Comenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.blre.2019.05.005_bb0005","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3324\/haematol.2013.094482","article-title":"Light chain amyloidosis: the heart of the problem","volume":"98","author":"Merlini","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2019.05.005_bb0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.6004\/jnccn.2007.0018","article-title":"Managing systemic light-chain amyloidosis","volume":"5","author":"Comenzo","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.blre.2019.05.005_bb0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/17474086.2014.858594","article-title":"Immunoglobulin light chain amyloidosis","volume":"7","author":"Merlini","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"14","key":"10.1016\/j.blre.2019.05.005_bb0020","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","article-title":"Amyloidosis: pathogenesis and new therapeutic options","volume":"29","author":"Merlini","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2019.05.005_bb0025","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2019.05.005_bb0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCHEARTFAILURE.108.788687","article-title":"Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition","volume":"1","author":"Biolo","year":"2008","journal-title":"Circ Heart Fail"},{"issue":"15","key":"10.1016\/j.blre.2019.05.005_bb0035","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2019.05.005_bb0040","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1586\/14779072.2015.1093936","article-title":"Novel strategies for the diagnosis and treatment of cardiac amyloidosis","volume":"13","author":"Palladini","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"15","key":"10.1016\/j.blre.2019.05.005_bb0045","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2019.05.005_bb0050","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"issue":"9371","key":"10.1016\/j.blre.2019.05.005_bb0055","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","article-title":"Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins","volume":"361","author":"Dispenzieri","year":"2003","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.blre.2019.05.005_bb0060","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2019.05.005_bb0065","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2019.05.005_bb0070","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2019.05.005_bb0075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2019.05.005_bb0080","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/ndt\/gfp201","article-title":"Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney","volume":"24","author":"Gertz","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"18","key":"10.1016\/j.blre.2019.05.005_bb0085","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2019.05.005_bb0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.2003.04433.x","article-title":"Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy","volume":"122","author":"Lachmann","year":"2003","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2019.05.005_bb0095","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1705106","article-title":"Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis","volume":"36","author":"Sanchorawala","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2019.05.005_bb0100","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","article-title":"Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL","volume":"107","author":"Palladini","year":"2006","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.blre.2019.05.005_bb0105","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2019.05.005_bb0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ajh.21948","article-title":"Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis","volume":"86","author":"Kumar","year":"2011","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2019.05.005_bb0115","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2010.30.5235","article-title":"Outcome in renal Al amyloidosis after chemotherapy","volume":"29","author":"Pinney","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.blre.2019.05.005_bb0120","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2019.05.005_bb0125","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2019.05.005_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3324\/haematol.2013.087619","article-title":"Update on treatment of light chain amyloidosis","volume":"99","author":"Mahmood","year":"2014","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2019.05.005_bb0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/21548331.1996.11443332","article-title":"Advances in the treatment of plasma cell diseases","volume":"31","author":"Comenzo","year":"1996","journal-title":"Hosp Pract (1995)"},{"issue":"7","key":"10.1016\/j.blre.2019.05.005_bb0140","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2019.05.005_bb0145","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/ajh.23828","article-title":"Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment","volume":"89","author":"Gertz","year":"2014","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.blre.2019.05.005_bb0150","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients","volume":"91","author":"Comenzo","year":"1998","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2019.05.005_bb0155","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.V128.22.646.646","article-title":"A randomized phase III trial of Melphalan and dexamethasone (MDex) versus Bortezomib, Melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis","volume":"128","author":"Kastritis","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2019.05.005_bb0160","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.bmt.1702178","article-title":"Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report","volume":"25","author":"Gertz","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2019.05.005_bb0165","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.bmt.1703200","article-title":"An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis","volume":"28","author":"Sanchorawala","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2019.05.005_bb0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1937-6448(08)00602-3","article-title":"Role of proteasomes in cellular regulation","volume":"267","author":"Konstantinova","year":"2008","journal-title":"Int Rev Cell Mol Biol"},{"issue":"4","key":"10.1016\/j.blre.2019.05.005_bb0175","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res"},{"issue":"37","key":"10.1016\/j.blre.2019.05.005_bb0180","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1038\/sj.onc.1205664","article-title":"Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1\/Akt signaling in human multiple myeloma cells: therapeutic implications","volume":"21","author":"Mitsiades","year":"2002","journal-title":"Oncogene"},{"issue":"15","key":"10.1016\/j.blre.2019.05.005_bb0185","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","article-title":"The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity","volume":"129","author":"Oliva","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2019.05.005_bb0190","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3324\/haematol.11627","article-title":"Efficacy of bortezomib in systemic AL amyloidosis with relapsed\/refractory clonal disease","volume":"93","author":"Wechalekar","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2019.05.005_bb0195","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2019.05.005_bb0200","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1182\/blood-2009-02-203398","article-title":"Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study","volume":"114","author":"Reece","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2019.05.005_bb0205","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2019.05.005_bb0210","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2019.05.005_bb0215","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2019.05.005_bb0220","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.clinthera.2013.08.015","article-title":"Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients","volume":"35","author":"Shah","year":"2013","journal-title":"Clin Ther"},{"issue":"22","key":"10.1016\/j.blre.2019.05.005_bb0225","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.5813.5813","article-title":"Once weekly subcutaneous Bortezomib, cyclophosphamide, and dexamethasone as induction therapy for all AL amyloidosis","volume":"128","author":"Abbas","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2019.05.005_bb0230","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2014.227","article-title":"Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients","volume":"28","author":"Palladini","year":"2014","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.blre.2019.05.005_bb0235","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2010-02-268987","article-title":"Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)","volume":"117","author":"Bochtler","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2019.05.005_bb0240","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.blre.2019.05.005_bb0245","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1200\/JCO.2015.62.3876","article-title":"A. Blaming the right fluorescent in situ hybridization","volume":"33","author":"Warsame","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.blre.2019.05.005_bb0250","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2019.05.005_bb0255","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2019.05.005_bb0260","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2019.05.005_bb0265","first-page":"287","article-title":"What is the functional role of the thalidomide binding protein cereblon?","volume":"2","author":"Chang","year":"2011","journal-title":"Int J Biochem Mol Biol"},{"issue":"9","key":"10.1016\/j.blre.2019.05.005_bb0270","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00018-010-0619-9","article-title":"Teratogenic effects of thalidomide: molecular mechanisms","volume":"68","author":"Ito","year":"2011","journal-title":"Cell Mol Life Sci"},{"issue":"6168","key":"10.1016\/j.blre.2019.05.005_bb0275","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.blre.2019.05.005_bb0280","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2019.05.005_bb0285","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4065\/75.9.897","article-title":"Thalidomide in the treatment of relapsed multiple myeloma","volume":"75","author":"Rajkumar","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.blre.2019.05.005_bb0290","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1053\/sonc.2001.28601","article-title":"Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma","volume":"28","author":"D'Amato","year":"2001","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2019.05.005_bb0295","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2019.05.005_bb0300","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2019.05.005_bb0305","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/13506120309041743","article-title":"Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis","volume":"10","author":"Dispenzieri","year":"2003","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.blre.2019.05.005_bb0310","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3816\/CLM.2003.n.005","article-title":"Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis","volume":"3","author":"Seldin","year":"2003","journal-title":"Clin Lymphoma"},{"issue":"4","key":"10.1016\/j.blre.2019.05.005_bb0315","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.thj.6200403","article-title":"Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma","volume":"5","author":"Palumbo","year":"2004","journal-title":"Hematol J"},{"issue":"7","key":"10.1016\/j.blre.2019.05.005_bb0320","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","article-title":"The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)","volume":"105","author":"Palladini","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2019.05.005_bb0325","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1445-5994.2005.01021.x","article-title":"Cardiac amyloidosis--sustained clinical and free light chain response to low dose thalidomide and corticosteroids","volume":"36","author":"Campbell","year":"2006","journal-title":"Intern Med J"},{"issue":"1","key":"10.1016\/j.blre.2019.05.005_bb0330","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijcard.2005.09.046","article-title":"An intriguing case of primary amyloidosis with cardiac involvement: symptomatic and echocardiographic improvement with thalidomide treatment","volume":"113","author":"Oh","year":"2006","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.blre.2019.05.005_bb0335","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.2007.06783.x","article-title":"Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +\/\u2212 thalidomide for systemic light-chain amyloidosis: results of a phase II trial","volume":"139","author":"Cohen","year":"2007","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.blre.2019.05.005_bb0340","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2019.05.005_bb0345","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2019.05.005_bb0350","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2019.05.005_bb0355","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2019.05.005_bb0360","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfq482","article-title":"Kidney dysfunction during lenalidomide treatment for AL amyloidosis","volume":"26","author":"Specter","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.blre.2019.05.005_bb0365","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-011-1244-x","article-title":"Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide","volume":"91","author":"Palladini","year":"2012","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.blre.2019.05.005_bb0370","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3324\/haematol.2016.163246","article-title":"Lenalidomide\/melphalan\/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up","volume":"102","author":"Hegenbart","year":"2017","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.blre.2019.05.005_bb0375","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood-2010-07-294405","article-title":"Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1\/2 dose-escalation study","volume":"116","author":"Moreau","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2019.05.005_bb0380","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1182\/blood-2011-12-396903","article-title":"A phase 1\/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis","volume":"119","author":"Kastritis","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2019.05.005_bb0385","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/blood-2012-01-407791","article-title":"Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2019.05.005_bb0390","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2019.05.005_bb0395","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2019.05.005_bb0400","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2019.05.005_bb0405","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.21822","article-title":"Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs","volume":"85","author":"Dispenzieri","year":"2010","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2019.05.005_bb0410","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.blre.2019.05.005_bb0415","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0167-5699(94)90148-1","article-title":"Human CD38: a glycoprotein in search of a function","volume":"15","author":"Malavasi","year":"1994","journal-title":"Immunol Today"},{"issue":"5","key":"10.1016\/j.blre.2019.05.005_bb0420","doi-asserted-by":"crossref","first-page":"L773","DOI":"10.1152\/ajplung.00217.2004","article-title":"CD38\/cyclic ADP-ribose signaling: role in the regulation of calcium homeostasis in airway smooth muscle","volume":"288","author":"Deshpande","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"10.1016\/j.blre.2019.05.005_bb0425","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2019.05.005_bb0430","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3389\/fimmu.2018.01676","article-title":"CD38 as immunotherapeutic target in light chain amyloidosis and multiple myeloma-association with molecular entities, risk, survival, and mechanisms of upfront resistance","volume":"9","author":"Seckinger","year":"2018","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.blre.2019.05.005_bb0435","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.05.005_bb0440","first-page":"507","article-title":"Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.05.005_bb0445","first-page":"508","article-title":"A prospective phase II of daratumumab in previously-treated systemic light-chain (AL) amyloidosis","volume":"130","author":"Roussel","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2019.05.005_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052686","article-title":"AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils","volume":"7","author":"Wall","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.blre.2019.05.005_bb0455","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.blre.2019.05.005_bb0460","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.V128.22.644.644","article-title":"NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion cohort of a phase 1\/2 study","volume":"128","author":"Gertz","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2019.05.005_bb0465","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64639-1","article-title":"Antibody-mediated resolution of light chain-associated amyloid deposits","volume":"157","author":"Hrncic","year":"2000","journal-title":"Am J Pathol"},{"issue":"10 Pt 2","key":"10.1016\/j.blre.2019.05.005_bb0470","first-page":"3831S","article-title":"Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4","volume":"9","author":"Solomon","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.05.005_bb0475","first-page":"509","article-title":"Final analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with relapsed or refractory AL amyloidosis","volume":"130","author":"Edwards","year":"2017","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.05.005_bb0480","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood-2018-99-118464","article-title":"Improvement in global longitudinal strain (GLS) correlates with NT-Probnp response in patients with cardiac amyloidosis treated on a phase 1b study of anti-amyloid Mab Cael-101","volume":"121","author":"Bhutani","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2019.05.005_bb0485","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJM199008233230803","article-title":"Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component","volume":"323","author":"Hawkins","year":"1990","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2019.05.005_bb0490","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"issue":"422","key":"10.1016\/j.blre.2019.05.005_bb0495","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Sci Transl Med"},{"issue":"1\u20132","key":"10.1016\/j.blre.2019.05.005_bb0500","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2013.09.015","article-title":"Reprogramming cell death: BCL2 family inhibition in hematological malignancies","volume":"155","author":"Scarfo","year":"2013","journal-title":"Immunol Lett"},{"issue":"2","key":"10.1016\/j.blre.2019.05.005_bb0505","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"10.1016\/j.blre.2019.05.005_bb0510","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2019.05.005_bb0515","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.3324\/haematol.2017.183749","article-title":"Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone","volume":"103","author":"Leung","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.05.005_bb0520","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.blre.2019.05.005_bb0525","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","journal-title":"FASEB J"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.05.005_bb0530","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.blre.2019.05.005_bb0535","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.blre.2019.05.005_bb0540","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.V120.21.3138.3138","article-title":"Doxycycline used as post transplant antibacterial prophylaxis improves survival in patients with light chain amyloidosis undergoing autologous stem cell transplantation","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2019.05.005_bb0545","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1073\/pnas.1220326110","article-title":"Insights into antiamyloidogenic properties of the green tea extract (\u2212)-epigallocatechin-3-gallate toward metal-associated amyloid-beta species","volume":"110","author":"Hyung","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"31","key":"10.1016\/j.blre.2019.05.005_bb0550","doi-asserted-by":"crossref","first-page":"21299","DOI":"10.1074\/jbc.M114.554667","article-title":"How epigallocatechin gallate can inhibit alpha-synuclein oligomer toxicity in vitro","volume":"289","author":"Lorenzen","year":"2014","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.blre.2019.05.005_bb0555","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood-2007-05-089243","article-title":"Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option?","volume":"110","author":"Hunstein","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2019.05.005_bb0560","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00392-008-0649-6","article-title":"Therapy effects of green tea in a patient with systemic light-chain amyloidosis","volume":"97","author":"Mereles","year":"2008","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"10.1016\/j.blre.2019.05.005_bb0565","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00392-010-0142-x","article-title":"Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis","volume":"99","author":"Mereles","year":"2010","journal-title":"Clin Res Cardiol"},{"issue":"13","key":"10.1016\/j.blre.2019.05.005_bb0570","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.blre.2019.05.005_bb0575","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bmt.1702005","article-title":"High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant","volume":"24","author":"Saba","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2019.05.005_bb0580","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach","volume":"99","author":"Palladini","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.blre.2019.05.005_bb0585","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/leu.2014.218","article-title":"A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis","volume":"28","author":"Venner","year":"2014","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.blre.2019.05.005_bb0590","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.blre.2019.05.005_bb0595","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2019.05.005_bb0600","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1373\/clinchem.2005.048017","article-title":"Serum free light chain measurements move to center stage","volume":"51","author":"Bradwell","year":"2005","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.blre.2019.05.005_bb0605","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.blre.2019.05.005_bb0610","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2019.05.005_bb0615","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2016.229","article-title":"Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis","volume":"31","author":"Landau","year":"2017","journal-title":"Leukemia"},{"issue":"32","key":"10.1016\/j.blre.2019.05.005_bb0620","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study","volume":"33","author":"D'Souza","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.05.005_bb0625","unstructured":"Nguyen VP, Landau H, Quillen K, Brauneis D, Shelton AC, Mendelson L, et al. Modified high-dose Melphalan and autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Biol Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.blre.2019.05.005_bb0630","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-12-2922","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease","volume":"19","author":"Agarwal","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.blre.2019.05.005_bb0635","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1200\/JCO.2014.56.2892","article-title":"Plasma cell neoplasms, their precursor states, and their prediction of organ damage","volume":"32","author":"Comenzo","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.05.005_bb0640","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2018-99-112902","article-title":"Seeking AL amyloidosis very early: the SAVE trial \u2014 identifying clonal lambda light chain genes in patients with MGUS or Smoldering multiple myeloma","volume":"132","author":"Zhou","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2019.05.005_bb0645","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.05.005_bb0650","first-page":"1836","article-title":"Minimal residual disease (MRD) assessed by flow Cytometry in patients with AL amyloidosis treated with cyclophosphamide, Bortezomib and dexamethasone (CyBorD)","volume":"130","author":"Jimenez-Zepeda","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2019.05.005_bb0655","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-018-0086-3","article-title":"Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis","volume":"8","author":"Kastritis","year":"2018","journal-title":"Blood Cancer J"},{"issue":"122","key":"10.1016\/j.blre.2019.05.005_bb0660","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1182\/blood.V128.22.3261.3261","article-title":"Persistence of minimal residual disease by multiparameter flow Cytometry can hinder recovery of organ damage in patients with AL amyloidosis otherwise in complete response","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2019.05.005_bb0665","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2017-12-819904","article-title":"Growth differentiation Factor 15 is a new biomarker for survival and renal outcomes in light chain (AL) amyloidosis","volume":"131","author":"Kastritis","year":"2018","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2019.05.005_bb0670","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18301383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18301383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:23:26Z","timestamp":1759436606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X18301383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":134,"alternative-id":["S0268960X18301383"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.05.005","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of novel therapies in the treatment of light chain amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100581"}}